Belmar Pharmacy

Belmar Pharmacy

Jack Kittle Jr. established Belmar Pharmacy in 1984 in Golden, Colorado, where it remains headquartered. The firm grew from a single retail pharmacy into a national-scale compounding operation, specializing in bioidentical hormone replacement therapy (BHRT) and customized medications for human and veterinary patients. The company's early focus on women's health and personalized hormone therapies created a defensible niche before compounding became a visible industry category (public record). Belmar operates across sterile and non-sterile compounding verticals. Its human-health line concentrates on bioidentical hormones, thyroid therapies, and dermatological formulations, while the veterinary division compounds medications for companion animals, including dosage forms not commercially manufactured. The company serves prescribing clinicians — primarily OB/GYNs, endocrinologists, and veterinarians — rather than selling direct-to-patient. The geographic footprint is national: Belmar ships compounded preparations to patients in all 50 U.S. states under state board of pharmacy registrations and FDA oversight frameworks applicable to 503A traditional compounding pharmacies. In 2016, the Kittle family sold a majority stake in Belmar to Denver-based private equity firm Excellere Partners, transitioning the company from founder-owned to institutionally backed. Jack Kittle Jr. remained involved through the transition (per PE Hub, 2016). The following year, in 2017, Belmar acquired Colorado-based compounding pharmacy Apocrx to expand its sterile-compounding capacity. By 2021, the company had become one of the five largest independent compounders in the U.S. by prescription volume (public record). Belmar's structural differentiator is its status as an independent, pharmacist-founded compounder inside an industry increasingly consolidated by private-equity roll-ups and pharmacy benefit manager (PBM) networks. Unlike chain-owned compounding units or hospital-based clean rooms, Belmar operates at scale while maintaining a single-location manufacturing model — a regulatory posture that keeps the firm under 503A compounding rules rather than the more capital-intensive 503B outsourcing-facility framework that governs bulk drug production.